Cancer remains a leading cause of death worldwide. However, the clinical community is fighting hard to finally beat the disease, while at the same time striving to find new ways to improve and extend patients’ lives. The Mundipharma network of independent associated companies is proud to be part of this endeavor and we are actively seeking alliances to develop new ‘smart’ chemotherapy options for underserved groups of patients with cancer.
In addition, we expect EDO (Mundipharma EDO GmbH) to play an important role in creating a future pipeline of oncology medicines. Based in Basel, Switzerland, EDO is part of the Mundipharma network. It is engaged in accelerating early stage assets in oncology on behalf of the network, with a focus on cancer types with limited treatment options available currently.
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.
Levact▼® / Ribomustin® / Ribovact® (bendamustine) – A chemotherapy agent for certain types of multiple myeloma, chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma.
Press return to search